Literature DB >> 18690320

Pigmented villonodular synovitis managed by Yttrium 90 after debulking surgery.

Hayati Ozturk1, Okay Bulut, Zekeriya Oztemur, Sema Bulut.   

Abstract

The goal of this study was to evaluate outcome of patients with pigmented villonodular synovitis (PVNS) managed by Yttrium90 (90Y) after debulking surgery. Seven patients (3 males and 4 females) with PVNS were studied retrospectively. Mean follow-up was 47.8 months (range 24-97 months). Mean age was 44.8 years (range 20-68 years. Debulking surgeries via arthroscopic synovectomy were performed in 4 cases and in 3 cases via mini arthrotomy. After 90Y injection was applied. Magnetic resonance imaging (MRI) included measurement of synovial thickness in preoperative and at last control. Main musculoskeletal tumor society score was 26 (range, 23-29), main MTS rating was 70.4% (range, 38.5-86.2%). Mean preoperative synovial thickness was 14.9mm range 20-12mm. Synovial thickness was completely disappeared at last MRI examination. There was diffuse joint effusion preoperatively, decreasing at last control. No cases of PVNS recurrence were found. Although we had a small number of cases, we believe that combination of debulking surgery with intra-articular injection of 90Y for PVNS of knee joint is an effective and safe treatment method.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18690320

Source DB:  PubMed          Journal:  Saudi Med J        ISSN: 0379-5284            Impact factor:   1.484


  2 in total

1.  Pigmented villonodular synovitis: a crowdsourcing study of two hundred and seventy two patients.

Authors:  Lizz van der Heijden; Sheila R Piner; Michiel Adrianus Josephus van de Sande
Journal:  Int Orthop       Date:  2016-05-12       Impact factor: 3.075

2.  Surgical synovectomy combined with yttrium 90 in patients with recurrent joint synovitis.

Authors:  Zekeriya Oztemür; Okay Bulut; Murat Korkmaz; Umut Hatay Gölge; Hayati Oztürk; Gündüz Tezeren; Ilhan Günaydın
Journal:  Rheumatol Int       Date:  2012-11-07       Impact factor: 2.631

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.